A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

ClinicalTrials.gov ID: NCT05696613

Public ClinicalTrials.gov record NCT05696613. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Superiority Study Comparing the Safety and Efficacy of SNP-ACTH (1-39) Gel Compared to Rituximab and FDA Approved Biosimilars in Adults With Primary Membranous Nephropathy (PMN) in a Two-Phase Adaptive Trial Design

Study identification

NCT ID: NCT05696613
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Cerium Pharmaceuticals, Inc.; Industry
Enrollment: 148 participants

Conditions and interventions

Conditions

Primary Membranous Nephropathy

Interventions

SNP-ACTH (1-39) Gel Drug
Rituximab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 12, 2023
Primary completion: Mar 31, 2027
Completion: Dec 30, 2027
Last update posted: Jun 24, 2026

2023 – 2027

United States locations

U.S. sites: 19
U.S. states: 9
U.S. cities: 18

Facility	City	State	ZIP	Site status
Academic Medical Research Institute	Los Angeles	California	90022	Recruiting
North America Research Institute	San Dimas	California	91773	Recruiting
Valiance Clinical Research	Tarzana	California	91356	Recruiting
RecioMed Clinical Research Network, Inc.	Boynton Beach	Florida	33472	Recruiting
South Florida Nephrology Research	Coral Springs	Florida	33071	Recruiting
Therafirst Medical Center	Fort Lauderdale	Florida	33308	Recruiting
Reliant Medical Research, LLC	Miami	Florida	33165	Recruiting
Vista Health Research, LLC	Miami	Florida	33176	Recruiting
Genesis Clinical Research	Tampa	Florida	33603	Recruiting
Fides Clinical Research	Atlanta	Georgia	30342	Recruiting
Costal Medical Research	Brunswick	Georgia	31520	Recruiting
Insight Hospital and Medical Center Chicago	Chicago	Illinois	60615	Recruiting
University of Iowa	Iowa City	Iowa	52242	Recruiting
Center for Advanced Kidney Research, PLC	Saint Clair Shores	Michigan	48080	Recruiting
NYU Langone Health	New York	New York	10016	Recruiting
Prolato Clinical Research Center	Houston	Texas	77054	Recruiting
P&I Clinical Research LLC	Lufkin	Texas	75904	Recruiting
University of Virginia	Charlottesville	Virginia	22908	Recruiting
Nephrology Associates of Northern Virginia	Fairfax	Virginia	22033	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05696613, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 24, 2026 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05696613 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →